Description

Syngene International provides clarification on news article regarding expansion of biologics facility to offer integrated antibody-drug conjugate (ADC) services from discovery through GMP manufacturing.

Summary

Syngene International Limited submitted a clarification to BSE and NSE on October 23, 2025 regarding a news article published in The Hindu Businessline about the company’s expansion of its biologics facility. The company confirmed the facts stated in the article regarding plans to provide fully integrated, end-to-end services for antibody-drug conjugates (ADCs) from discovery through GMP manufacturing. The company clarified that this investment in bioconjugation capabilities is in the ordinary course of business and does not meet materiality thresholds under SEBI Listing Regulations.

Key Points

  • Company confirms plans to provide fully integrated, end-to-end services for antibody-drug conjugates (ADCs)
  • Services will span from discovery through GMP manufacturing
  • New suite will enable both Monoclonal Antibodies (mAb) production and GMP bioconjugation at a single site
  • Investment complements existing commercial capabilities in payload and linker manufacturing
  • Company states the investment is in ordinary course of business
  • Investment does not meet materiality criteria under Regulation 30 of SEBI Listing Regulations
  • Does not meet criteria specified under Industry Standards Note (ISN) or Clause 4 of Para B of Part A of Schedule III

Regulatory Changes

No regulatory changes announced. This is a clarification disclosure submitted under Regulation 30 of SEBI (Listing Obligations and Disclosures) Regulations, 2015 in response to exchange query about news article.

Compliance Requirements

  • Disclosure made in compliance with Regulation 30 of SEBI Listing Regulations
  • Information made available on company website www.syngeneintl.com
  • No additional compliance requirements for market participants

Important Dates

  • October 23, 2025: Date of exchange query and company clarification
  • October 23, 2025: Reference date of company letter (Ref: Syn/CS/SE/Reg 30/2025-26/Oct/06)

Impact Assessment

Minimal market impact as this is a clarification of publicly available news about routine business expansion. The company explicitly states the investment does not meet materiality thresholds, indicating it is not expected to significantly affect the company’s financial position or operations. The expansion strengthens Syngene’s biologics capabilities in the ADC space, which may have positive long-term strategic implications for the company’s service offerings in the pharmaceutical contract research and manufacturing sector. No immediate trading or operational impact on other market participants.

Impact Justification

Routine disclosure clarifying news article about non-material business expansion in ordinary course of business; does not meet materiality criteria under SEBI Listing Regulations